Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Solta Medical Corporation, a subsidiary of Bausch Health Companies Inc. (BHC), has appointed Gary Gemignani as Chief Financial Officer, effective March 28, 2022. Gemignani brings over 35 years of experience in finance, previously serving as CFO for various pharmaceutical firms. His extensive background is expected to support Solta as it prepares for a potential IPO following a public filing on February 8, 2022. The IPO will involve Solta’s common shares, pending market conditions and regulatory approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced new analyses for its dermatology products IDP-126 Gel, DUOBRII®, and SILIQ® at the AAD Annual Meeting from March 25-29, 2022. The investigational IDP-126 Gel aims to treat moderate-to-severe acne and could become a first-in-class therapy if approved. DUOBRII® effectiveness for maintaining skin clearance was also highlighted. Additionally, the company introduced a JUBLIA® virtual reality experience to educate about onychomycosis, impacting 35 million people in the U.S. annually.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in two upcoming investor conferences. The events include the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 11:15 a.m. ET. Key executives participating include Joseph C. Papa, Sam Eldessouky, and Arthur J. Shannon. Live webcasts will be available on the company's Investor Relations page.
Bausch Health Companies (NYSE/TSX: BHC) announces the opening of applications for the 2022 Aspire Higher Scholarship program, targeting students affected by dermatologic conditions. The program, active since 2013, will award nine scholarships of up to $10,000 each to aid educational pursuits. Applicants must submit recommendations and an essay detailing their experiences. This initiative has granted 60 scholarships totaling $828,000 over the years. Applications are open until May 31, 2022, with recipients announced in summer 2022.
On March 1, 2022, Salix Pharmaceuticals, part of Bausch Health (NYSE: BHC), partnered with the Colon Cancer Coalition to promote colorectal cancer screening awareness. The initiative, known as the Faces of Blue campaign, will share patient stories to encourage screenings, especially following the U.S. Preventive Services Task Force's guideline lowering the screening age to 45. This change affects approximately 45 million Americans now eligible for early detection screenings. Salix aims to enhance education and outreach through new resources and social media partnerships.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced participation in the J.P. Morgan Global High Yield & Leveraged Finance Conference on March 1, 2022, at 9:15 a.m. ET. Key executives, including CFO Sam Eldessouky and SVP Arthur J. Shannon, will represent the company. Bausch Health focuses on improving health with a range of products in eye health, gastroenterology, and dermatology. The company's commitment to advancing global health and innovative solutions is highlighted.
Bausch Health reported its fourth-quarter and full-year 2021 financial results, revealing revenues of $2.196 billion for Q4 and $8.434 billion for the full year, up 5% from 2020. Despite a net income of $69 million in Q4, the company faced a full-year net loss of $948 million. Noteworthy achievements include the successful launch of four new products and progress in IPO preparations for Bausch + Lomb and Solta. However, cash generated from operations dropped significantly by 94% in Q4, emphasizing operational challenges.
Bausch Health Companies (NYSE/TSX: BHC) announced the U.S. launch of the OraFit™ custom clear aligner system on Feb. 22, 2022, aimed at correcting malocclusion. This system features a three-layer design with high-performance materials, providing a comfortable and aesthetically pleasing option for patients. With malocclusion affecting approximately 66% of individuals in the U.S., OraFit™ offers dentists a new solution that promotes patient acceptance and compliance. It also integrates a user-friendly online resource for dental professionals to streamline case submissions.
Bausch Health and its gastroenterology division, Salix Pharmaceuticals, have announced the opening of the 2022 Salix Gastrointestinal Health Scholars Program. This initiative will award scholarships of up to $10,000 to 10 students living with gastrointestinal diseases who are pursuing higher education. The application period runs until May 15, 2022, with recipient notifications expected in the summer. The program includes various awards categories, emphasizing the company’s commitment to supporting students.
KBRA has published its Fourth-Quarter 2021 U.S. Bank Compendium, offering insights into the U.S. banking sector's performance and credit metrics for the quarter. The report includes analyses of actions by larger banks regarding overdraft fees and features a quarterly ESG Bulletin. Notable highlights include summaries of publicly traded U.S. banks, key performance metrics, and data on top deposit franchises. Atlantic Union Bankshares Corporation (NASDAQ: AUB) is rated BBB+ with a positive outlook. For detailed insights, the full report is accessible online.